Related Experiment Video
Updated: Jan 7, 2026
Author Spotlight: Advancements in PBMC Isolation – Enhancing Throughput and Consistency in Research
Published on: July 19, 2024
Processing of peripheral blood progenitor cell components in improved clean areas does not reduce the rate of
Uwe Cassens1, Christoph Ahlke, Henk Garritsen
1Department of Transfusion Medicine/Transplantation Immunology, University Hospital Münster, Germany. cassenu@uni-muenster.de
Background:
Microbial contamination of peripheral blood progenitor cell components (PBPCs) may cause severe complications in immunosuppressed recipients. Therefore, principles of Good Manufacturing Practice (GMP) are applicable for processing of PBPC components to reduce potential risks of contamination.
Study Design And Methods:
It was investigated in a retrospective study whether the microbial contamination of PBPC components could be reduced after processing in improved clean areas according to the "Manufacture of Sterile Medicinal Products." Starting in 1994, a total of 1478 autologous and allogeneic PBPC components have been collected and processed into 3149 cryopreservation bags at the Department of Transfusion Medicine. Sterility testing was performed for all bags. Until December 1998, 783 PBPC components were processed at a clean bench only (group I). Thereafter, 695 PBPC components have been processed at a clean bench located in a clean area with an airlock system for personnel and equipment (group II).
Results:
In group I, 16 of 1555 bags (1.03%) showed positive results in the first sterility testing. In group II, 21 of 1594 bags (1.32%) were positive (p = NS). The clinical follow-up was inconspicuous.
Conclusion:
Microbial contamination of PBPC components could not be reduced by installation of improved clean area conditions.
Insights
Improved clean areas did not reduce microbial contamination in peripheral blood progenitor cell (PBPC) components. Sterility testing results showed no significant difference between processing methods, indicating current practices are insufficient for reducing contamination risks.
Area of Science:
- Transfusion Medicine
- Microbiology
- Good Manufacturing Practice (GMP)
Background:
- Microbial contamination of peripheral blood progenitor cell (PBPC) components poses risks to immunosuppressed recipients.
- Good Manufacturing Practice (GMP) principles are crucial for processing PBPC components to mitigate contamination.
- Ensuring the sterility of PBPC components is vital for patient safety in transplantation.
Purpose of the Study:
- To evaluate the impact of improved clean area conditions on microbial contamination of PBPC components.
- To determine if enhanced sterile processing environments reduce contamination rates in PBPC collections.
- To assess the effectiveness of upgraded cleanroom facilities in maintaining PBPC sterility.
Main Methods:
- A retrospective study compared microbial contamination rates before and after implementing improved clean areas.
- Peripheral blood progenitor cell (PBPC) components were processed using either a clean bench or a clean bench within an enhanced clean area with an airlock.
- Sterility testing was performed on all cryopreserved PBPC bags, with 1478 components processed in total.
Main Results:
- No statistically significant reduction in microbial contamination was observed after implementing improved clean area conditions.
- The contamination rate in group I (clean bench only) was 1.03%, while group II (enhanced clean area) showed a rate of 1.32%.
- Clinical follow-up data did not reveal any complications related to contamination in either group.
Conclusions:
- Installation of improved clean area conditions did not effectively reduce microbial contamination in PBPC components.
- Current sterile processing enhancements may not be sufficient to prevent microbial contamination in PBPC collections.
- Further investigation into advanced aseptic processing techniques is warranted to improve PBPC component safety.
